This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Daclatasvir and Sofosbuvir contain active agents Daclatasvir and Sofosbuvir. It is an antiviral medication used to treat chronic hepatitis C (HCV) infections. Hepatitis C infection is a liver disease caused by the hepatitis C virus (HCV). Talk to your doctor if you have liver problems other than hepatitis C infection, had a liver transplant, diabetes, heart disorders, severe kidney problems, or are on dialysis before taking Daclatasvir and Sofosbuvir. Your physician will perform blood tests to check for hepatitis B virus infection before starting treatment with this medicine, as this medicine can reactivate the hepatitis B virus. Daclatasvir was approved on July 24, 2015, and Sofosbuvir was approved on December 6, 2013.
Mechanism of Action of undefined
Daclatasvir is a direct-acting antiviral medication that works by inhibiting a protein called NS5A, which is essential for the replication of the hepatitis C virus. Sofosbuvir is another direct-acting antiviral medication that works by inhibiting a different protein called NS5B, which is also essential for the replication of the hepatitis C virus. These are used to increase its effectiveness in treating HCV.
Uses of undefined
Daclatasvir and Sofosbuvir are used to Treatment of chronic hepatitis C virus (HCV) infection.
undefined Drug administaration and Dosage available
Take Daclatasvir and Sofosbuvir exactly as prescribed by your doctor. The recommended dose and dosing schedule may vary depending on your medical condition, age, weight, and other factors. It should be taken with food. Swallow the tablet as a whole with a glass of water. Patients should not chew, crush, or break the tablet, as this may affect the effectiveness of the medication. Avoid doubling the dose to compensate for the missed dose.
Warnings, Precautions and Side Effects of undefined
Daclatasvir and Sofosbuvir can cause serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These reactions can be life-threatening. Patients with advanced liver cirrhosis may have an increased risk of liver failure or other serious complications during treatment with this medicine. In some cases virus develops resistance to these medications, and treatment may become less effective.
Patients who develop skin reactions require immediate medical attention if they occur. Cirrhosis patients require additional monitoring or treatment modifications to minimize the risk of complications. Patients who do not respond to Daclatasvir and Sofosbuvir may require alternative treatment options.
Daclatasvir and Sofosbuvir's most common side effects include headache, fatigue, nausea, and insomnia. Other common side effects may include diarrhea, muscle aches, and irritability. Some patients may experience more serious side effects, such as liver problems, allergic reactions, or anemia.
Word Of Advice
If you have been prescribed Daclatasvir and Sofosbuvir, following your doctor's instructions is important. Suppose you experience any unusual symptoms or side effects while taking this medicine, such as fever, persistent cough, difficulty breathing, abdominal pain, or signs of liver dysfunction. In such a case, you should contact your doctor immediately. Do not stop medication without first consulting your doctor, as this may affect the effectiveness of the medication and your treatment outcomes. Pregnant and breastfeeding women should consult with a healthcare provider before taking it. Special caution should be taken when this medication is used in the elderly and pediatrics. Avoid close contact with an infected person, as this medication lowers the immune system. Always maintain a healthy and balanced diet to support your overall health and well-being.
Frequently Asked Question
- Bristol-Myers Squibb Company, US Food and Drug Administration, [Revised on Feb 2017] [Accessed on 12th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf
- Gilead Sciences Ireland UC, European Medical Agency (ema), [Revised on Sept 2018] [ Accessed on 12th May 2023], https://www.ema.europa.eu/en/documents/product-information/sovaldi-epar-product-information_en.pdf
- Gilead Sciences, US Food, and Drug Administration, [ Revised on August 2015] [ Accessed on 12th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s002lbl.pdf
The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.